Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Int J Gynaecol Obstet. 2005 Jan;88(1):15-8.

    L-Arginine treatment for asymmetric fetal growth restriction.

    Source

    Department of Gynecology/Obstetrics, First Affiliated Hospital of Jinan University, Guangzhou, China.

    Abstract

    OBJECTIVES:

    [corrected] To investigate the effects of L-Arginine in treating asymmetric fetal growth restriction (FGR).

    METHODS:

    A total of 66 pregnant women whose fetuses were diagnosed with asymmetric fetal growth restriction were divided into two groups. Group 1 consisted of 36 women who were given routine therapy alone; group 2 consisted of 30 women who were given L-Arginine and routine therapy; and the control group consisted of 30 more women with a normal pregnancy.

    RESULTS:

    Before treatment, mean maternal serum levels of NO2-/NO3- were significantly lower in groups 1 and 2 than in the control group (P<0.01). After treatment, maternal serum levels of NO2-/NO3- were considerably higher in group 2 than in group 1 (P<0.01). Mean birth weight was significantly higher in group 2 than in group 1 (P<0.05), but still lower in group 2 than in the control group (P<0.01).

    CONCLUSIONS:

    A deficiency in nitric oxide may play an important role in the development of asymmetric fetal growth restriction. L-Arginine can be used to increase maternal NO2-/NO3- levels and newborn birth weight.

    PMID:
    15617699
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk